sorafenib has been researched along with dactinomycin in 5 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (dactinomycin) | Trials (dactinomycin) | Recent Studies (post-2010) (dactinomycin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 19,045 | 355 | 969 |
| Protein | Taxonomy | sorafenib (IC50) | dactinomycin (IC50) |
|---|---|---|---|
| RAD51 | Homo sapiens (human) | 32.1 | |
| Growth factor receptor-bound protein 2 | Homo sapiens (human) | 5 | |
| Discoidin domain-containing receptor 2 | Homo sapiens (human) | 9 | |
| Growth factor receptor-bound protein 2 | Mus musculus (house mouse) | 5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, K; Li, Y; Lu, X; Ren, X | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Pappo, A; Paulino, AC | 1 |
| Chen, YJ; Hsu, ML; Huang, WP; Huang, YC; Ko, WC; Lee, JJ; Lin, JC; Liu, CL; Liu, TP; Wu, CH | 1 |
| Chen, D; Eyupoglu, IY; Savaskan, N | 1 |
2 review(s) available for sorafenib and dactinomycin
| Article | Year |
|---|---|
Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.
Topics: Amino Acid Sequence; Animals; Discoidin Domain Receptors; Drug Discovery; Humans; Inflammation; Ligands; Models, Molecular; Molecular Sequence Data; Neoplasms; Protein Conformation; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; Small Molecule Libraries | 2015 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for sorafenib and dactinomycin
| Article | Year |
|---|---|
Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Child; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Dactinomycin; Etoposide; Fatal Outcome; Female; Foot; Groin; Humans; Ifosfamide; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Lymphatic System; Male; Niacinamide; Phenylurea Compounds; Pyridines; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Rhabdomyosarcoma, Alveolar; Salvage Therapy; Soft Tissue Neoplasms; Sorafenib; Temozolomide; Thigh; Vincristine | 2009 |
Sorafenib induces autophagy in human myeloid dendritic cells and prolongs survival of skin allografts.
Topics: Animals; Antigens; Autophagy; Cell Survival; Dactinomycin; Dendritic Cells; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Mice; Microscopy, Fluorescence; Myeloid Cells; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Skin Transplantation; Sorafenib; Transplantation, Homologous | 2013 |
Ferroptosis and Cell Death Analysis by Flow Cytometry.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dactinomycin; Flow Cytometry; Humans; Indicators and Reagents; Iron; Necrosis; Niacinamide; Phenylurea Compounds; Piperazines; Propidium; Rats; Sorafenib | 2017 |